CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Abstract Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML relapse thereby negatively impacting disease outcome. Over the last years myeloid de...

Full description

Bibliographic Details
Main Authors: Regina Jitschin, Domenica Saul, Martina Braun, Sehmus Tohumeken, Simon Völkl, Roman Kischel, Michael Lutteropp, Cedric Dos Santos, Andreas Mackensen, Dimitrios Mougiakakos
Format: Article
Language:English
Published: BMJ Publishing Group 2018-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Acute myeloid leukemia
Myeloid derived suppressor cells
Bispecific antibodies
Online Access:http://link.springer.com/article/10.1186/s40425-018-0432-9

Internet

http://link.springer.com/article/10.1186/s40425-018-0432-9

Similar Items